Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS: By the Numbers: Real-World Impact of Rising Drug Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/16/2017 | 01:55pm CEST

Release date- 15062017 - CVS Health - Prescription drug prices continue to be a serious concern as rising prices outpace overall health care inflation. In 2015 alone, 16.7 percent of all U.S. health care dollars was spent on prescription drugs.

This rise in costs not only places a heavy burden on patients and payors, it ultimately affects U.S. taxpayers. To understand the real-world impact of rising drug costs on Americans, we conducted a survey of 2,195 registered voters in April 2017.

Voters are Overwhelmingly Concerned

Eighty-eight percent of respondents report being somewhat or very concerned about the high cost of prescription drugs. A higher percentage of women than men report being very concerned about drug prices (60 percent vs. 47 percent, respectively). Voters aged 45-65 are more likely to report concern than their younger counterparts, as are voters who take three or more prescription drugs.

Many Believe Increasing Competition and Accelerating Drug Reviews Can Help

Nearly one in two (47 percent) voters believe that there aren't enough different prescription drugs available to patients to treat their diseases and conditions. Forty-seven percent also believe that there is not enough competition in the pharmaceutical marketplace. Among voters aged 55-64, that number jumps to 60 percent.

There is, however, majority support for quicker market entry of lower-cost alternatives to brand-name drugs. Fifty-eight percent of respondents are supportive of proposals to speed up FDA approval of biosimilar drugs, which are near-identical copies of original biologic products; this means that there are no clinically significant differences in safety and efficacy.

CVS Health is Committed to Making Medications More Accessible and Affordable

We employ industry-leading strategies to encourage more competitive pricing and reduce costs for patients and payors. For example:

CVS Caremark uses industry expertise to negotiate discounts with manufacturers. These are passed on to plan sponsors and can be used to lower premiums or reduce cost-sharing for consumers.

We developed the capability for clients to apply negotiated discounts at the point-of-sale, to reduce a member's out-of-pocket cost for a prescription when they are at the pharmacy counter.

By encouraging the use of lower-cost, clinically equivalent medicines, such as generics and biosimilars, we can help patients achieve the same health outcomes at a more affordable cost.

We also lower costs through the Reduced RxTM program, which helps patients with high out-of-pocket costs afford their medications.

For more information on how CVS Health is working to ensure consumers have access to affordable medicines, visit our Rising Drug Prices information center. And to stay informed about the most talked-about topics in health care, register for content alerts and our bi-weekly health care newsletter.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
08/17 CVS PHARMACY : Earns URAC Reaccreditation in Community Pharmacy
08/17 CONSIDER YOUR PURPOSE : PA and PharmD Students Receive Short White Coats
08/16 CVS HEALTH : Prom night at YMCA Camp Oakes
08/16 CVS HEALTH : Survey Reveals Two in Three Americans who plan to get a Flu Shot Be..
08/15 CVS : Promoting Medication Adherence
08/11 FARUQI & FARUQI, LLP : is Investigating CVS Health Corporation (CVS) on Behalf o..
08/11 CVS : Delivering The Right Care at the Right Time
08/10 CVS : Recruiting Mature Workers
08/10 CVS : Talent Is Ageless
08/09 CVS tops 2Q forecasts despite sales slump
More news
News from SeekingAlpha
08/17 TARGET REPORTS Q2 : Updating My Bullish Comments From Last Month
08/17 Bert's August Dividend Stock Watch List
08/17 CVS HEALTH VS. WALGREENS BOOTS ALLIA : Which Drugstore Is The 'Best' Buy Now?
08/16 CVS Is Going Back Towards $100
08/15 BETTER DIVIDEND GROWTH STOCK BUY TOD : CVS Or Walgreens Boots Alliance?
Financials ($)
Sales 2017 184 098 M
EBIT 2017 10 053 M
Net income 2017 5 304 M
Debt 2017 24 744 M
Yield 2017 2,50%
P/E ratio 2017 15,67
P/E ratio 2018 13,39
EV / Sales 2017 0,57x
EV / Sales 2018 0,55x
Capitalization 80 197 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 86,6 $
Spread / Average Target 9,8%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-0.03%80 197
WALGREENS BOOTS ALLIANCE-2.26%86 560
EXPRESS SCRIPTS HOLDING CO-11.27%35 254
MCKESSON CORPORATION4.54%30 873
CARDINAL HEALTH INC-9.46%20 620
AMERISOURCEBERGEN CORP.2.35%17 516